Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AININCAR
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
AININCAR is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule drugs targeting difficult-to-treat cancers, with a particular emphasis on the RAS signaling pathway. The company utilizes a proprietary structure-based drug design platform to develop highly selective inhibitors for various KRAS mutations, including G12D, G12C, and G12V. Its lead programs are currently undergoing clinical evaluation for solid tumors such as non-small cell lung cancer and pancreatic cancer. AININCAR aims to address significant unmet medical needs in oncology through precision medicine and rational drug design.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeAntibodyBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on AININCAR.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AININCAR.